Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption

NCT01069809 is registered in ClinicalTrials.gov with Argos Therapeutics as lead sponsor.

NCT NCT01069809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01069809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Lead sponsor
Argos Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2010
Completion date
September 30, 2015
Enrollment
53 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection